About Welchol

Consider Welchol as add-on therapy for lowering LDL-C and A1C

In the appropriate patient, as an adjunct to diet and exercise, Welchol (colesevelam HCI) is the only bile acid sequestrant FDA approved to provide both LDL-C and A1C reductions in adults with primary hyperlipidemia and type 2 diabetes mellitus (T2DM) when used in combination with a statin and metformin.

The Welchol difference–more reasons to prescribe Welchol:

Welchol is the only FDA-approved therapy for lowering LDL-C and A1C with one active ingredient in adults with primary hyperlipidemia and T2DM¹
Prescribed by physicians to reduce LDL-C for over 15 years with over 22 million prescriptions written
In T2DM clinical trials, not associated with weight gain
Welchol works in combination with the standards of care, statins and metformin, to reduce LDL-C and A1C
Welchol does not require a dosage adjustment in patients with hepatic impairment or mild or moderate renal impairment (Welchol has not been studied in patients with severe renal impairment)
In T2DM clinical trials, incidence of hypoglycemia was comparable between Welchol and placebo
Welchol delivers efficacy without being systemically absorbed and is not metabolized by the liver or kidneys¹

Welchol® (colesevelam HCI) reduces LDL-C and improves glycemic control

Welchol is contraindicated in patients with serum triglyceride (TG) concentrations > 500 mg/dL, in patients with a history of hypertriglyceridemia-induced pancreatitis, and in patients with a history of bowel obstruction.

Welchol may increase the exposure of co-administered metformin extended release (ER). Patients receiving concomitant metformin ER and colesevelam should be monitored for clinical response as is usual for the use of antidiabetes drugs.

Please see Important Limitations of Use and Important Safety Information about Welchol below.

Welchol Savings for Your Patients

Based on a $0 co-pay for a 90-day supply or a $10 co-pay for a 30-day supply. Restrictions apply based on eligibility. See Terms & Conditions below.

PRINT SAVINGS
CARD NOW

Based on a $0 co-pay for a 90-day supply or a $10 co-pay for a 30-day supply. Restrictions apply based on eligibility. See Terms & Conditions below.

PRINT SAVINGS
CARD NOW

NEXT: How Welchol Works

Indications

Welchol is indicated as an adjunct to diet and exercise to:

reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hyperlipidemia
reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH)
improve glycemic control in adults with type 2 diabetes mellitus

Limitations of Use

Welchol should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis
The effect of Welchol on cardiovascular morbidity and mortality has not been determined.
Welchol has not been studied in type 2 diabetes in combination with a dipeptidyl peptidase-4 inhibitor
Welchol has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias
Welchol has not been studied in children younger than 10 years of age or in premenarchal girls

Savings Card Offer: Eligibility Criteria and Terms & Conditions

To the Patient: You must present this card to the pharmacist along with your WELCHOL^® (colesevelam HCl) prescription to participate in the program. For patients with commercial insurance, savings per prescription of WELCHOL will apply after the following out‐of‐pocket expenses are met: $10 per prescription for a 30‐day supply of WELCHOL or $0 per prescription for a 90‐day supply of WELCHOL. Offer may not be combined with any other program offer or discount for WELCHOL. Savings for WELCHOL are subject to a maximum benefit of $150 per 30‐day prescription or $450 per 90‐day prescription. If you have questions regarding your eligibility or benefits, or wish to discontinue participation, call (877) 264‐2440
(8 AM – 8 PM ET, Monday‐Friday). When you use this card, you are certifying that you understand the program rules, regulations, and terms and conditions. You are not eligible if you are enrolled in any state or federal health care program, including, but not limited to, Medicare Part D or Medicaid, VA, DOD, or TRICARE/CHAMPUS; or where taxed, restricted, or prohibited by law; or if you do not otherwise comply with the terms of this card. Further, you agree to discontinue using the card if you enroll in any state or federal health care program during the program period. Offer valid in US and Puerto Rico only.

To the Pharmacist: When you use this card, you are certifying that the patient is not enrolled in any federal, state, or other governmental programs for this prescription.

Submit transaction to McKesson Corporation, using BIN #610524.
If primary coverage exists, input card information as secondary coverage and transmit using the COB segment of NCPDP transaction. Applicable discounts will be displayed in the transaction response.
Acceptance of this card is subject to LoyaltyScript^® program Terms and Conditions posted at www.mckesson.com/mprstnc.
Patient not eligible if enrolled in any state or federal health care program, including, but not limited to, Medicare Part D or Medicaid, VA, DOD, or TRICARE/CHAMPUS, or where taxed, restricted, or prohibited by law. Offer valid in US and Puerto Rico only.
The LoyaltyScript^® card is not valid for use with any other prescription drug discount or cash cards for WELCHOL. Claims submitted utilizing the program are subject to audit or validation.
LoyaltyScript^® is not an insurance card.

Cosette Pharmaceuticals, Inc., reserves the right to rescind, revoke, or amend this program, at any time, without notice.

Trademarks not owned by Cosette Pharmaceuticals, Inc., are property of their respective owners.